This dual mechanism of disrupting immunosuppressive signaling via the CD70–CD27 axis and inducing genotoxic stress positions CD70 as an attractive therapeutic target currently being assessed in a first-in-human Phase I trial for advanced solid tumors, including NPC [86]. Here, CD70 is linked to nasopharyngeal carcinoma.